NEW YORK, Sept. 06, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Foundation Medicine, Inc. (NASDAQ:FMI) who purchased shares between February 26, 2014 and November 3, 2015. The action, which was filed in the USDC for the District of Massachusetts, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the Class Period, defendants made materially false and/or misleading statements and/or failed to disclose material information regarding: (1) the reimbursement process and likelihood of coverage for Foundation’s tumor tests by Medicare; and (2) the Company’s financial guidance. As a result of these false statements, Foundation common stock traded at artificially inflated prices during the Class Period.
On July 29, 2015, the Company disclosed that it was not making the strides obtaining coverage it had claimed to have been making during the Class Period, and that Foundation would receive no Medicare payments in 2015 for its tumor profiling tests due to a delay in receiving a local coverage determination from its regional Medicare Administrative Contractor. As a result of the delay, the Company slashed its 2015 financial guidance, which, unbeknownst to investors, was based on an assumption that Medicare approval was going to be obtained in 2015. Then, on November 3, 2015, the Company disclosed a further revision to the already reduced number of clinical tests it expected to report for 2015.
Shareholders have until September 26, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sbm/foundation-medicine-inc?wire=3.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th Floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com


Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Luxury Car Sales in the Middle East Take a Hit Amid Iran War
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 



